BioClin scores a $30M raise from marquee investors to fuel mid-stage work on a new cancer drug
BioClin Therapeutics has rounded up a fresh load of cash to fuel some mid-stage trial work on its lead — and currently sole — cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
